Literature DB >> 20679607

Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

Ronan J Kelly1, Corey Carter, Giuseppe Giaccone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20679607      PMCID： PMC7301570          DOI： 10.1200/JCO.2010.29.3126

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

1.  ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Authors:  D Graus-Porta; R R Beerli; J M Daly; N E Hynes
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

2.  Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?

Authors:  David H Johnson; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

3.  HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Lynne Bemis; Marileila Varella-Garcia
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.

Authors:  Lee M Krug; Vincent A Miller; Jyoti Patel; John Crapanzano; Christopher G Azzoli; Jorge Gomez; Mark G Kris; Robert T Heelan; Barbara Pizzo; Leslie Tyson; Christine Sheehan; Jeffrey S Ross; Ennapadam Venkatraman
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

5.  Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis.

Authors:  Haruhiko Nakamura; Norihito Kawasaki; Masahiko Taguchi; Kazuyuki Kabasawa
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

6.  Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

Authors:  Federico Cappuzzo; Marileila Varella-Garcia; Hisayuki Shigematsu; Irene Domenichini; Stefania Bartolini; Giovanni L Ceresoli; Elisa Rossi; Vienna Ludovini; Vanesa Gregorc; Luca Toschi; Wilbur A Franklin; Lucio Crino; Adi F Gazdar; Paul A Bunn; Fred R Hirsch
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

7.  HER2/neu expression in malignant lung tumors.

Authors:  Fred R Hirsch; Wilbur A Franklin; Robert Veve; Marileila Varella-Garcia; Paul A Bunn
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

8.  Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

Authors:  Gerald Clamon; James Herndon; Jeffrey Kern; Ramaswamy Govindan; Jennifer Garst; Dorothy Watson; Mark Green
Journal:  Cancer       Date:  2005-04-15       Impact factor: 6.860

9.  Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.

Authors:  C Papila; H Uzun; H Balci; H Zerdali; C Sezgin; Günay Can; H Yanardag
Journal:  Med Oncol       Date:  2008-10-15       Impact factor: 3.064

10.  Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.

Authors:  Roy S Herbst; Angela M Davies; Ronald B Natale; Thao P Dang; Joan H Schiller; Linda L Garland; Vincent A Miller; David Mendelson; Annick D Van den Abbeele; Yulia Melenevsky; Daniel J de Vries; David A Eberhard; Benjamin Lyons; Stuart G Lutzker; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531
View more
  13 in total

Review 1.  New targetable oncogenes in non-small-cell lung cancer.

Authors:  Geoffrey R Oxnard; Adam Binder; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

Review 2.  EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Authors:  Yuxin Lin; Xian Wang; Hongchuan Jin
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

3.  Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.

Authors:  Xu Zhang; Khoa Dang Nguyen; Paul A Rudnick; Nitin Roper; Emily Kawaler; Tapan K Maity; Shivangi Awasthi; Shaojian Gao; Romi Biswas; Abhilash Venugopalan; Constance M Cultraro; David Fenyö; Udayan Guha
Journal:  Mol Cell Proteomics       Date:  2019-01-07       Impact factor: 5.911

4.  HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Authors:  Rathi N Pillai; Madhusmita Behera; Lynne D Berry; Mike R Rossi; Mark G Kris; Bruce E Johnson; Paul A Bunn; Suresh S Ramalingam; Fadlo R Khuri
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860

5.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Authors:  Nikhil Wagle; Caroline Emery; Michael F Berger; Matthew J Davis; Allison Sawyer; Panisa Pochanard; Sarah M Kehoe; Cory M Johannessen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

6.  Identification of driver mutations in lung cancer: first step in personalized cancer.

Authors:  David Planchard
Journal:  Target Oncol       Date:  2013-02-01       Impact factor: 4.493

Review 7.  Targeted therapy for non-small-cell lung cancer: past, present and future.

Authors:  Patrick M Forde; David S Ettinger
Journal:  Expert Rev Anticancer Ther       Date:  2013-06       Impact factor: 4.512

8.  Phase II trial of dacomitinib in patients with HER2-positive gastric cancer.

Authors:  Do-Youn Oh; Kewn-Wook Lee; Jae Yong Cho; Won Ki Kang; Seock-Ah Im; Jin Won Kim; Yung-Jue Bang
Journal:  Gastric Cancer       Date:  2015-11-18       Impact factor: 7.370

9.  Unraveling the autoimmune translational research process layer by layer.

Authors:  Richard S Blumberg; Bonnie Dittel; David Hafler; Matthias von Herrath; Frank O Nestle
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

10.  AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.

Authors:  Hua Xie; Liping Lin; Linjiang Tong; Yong Jiang; Mingyue Zheng; Zhuo Chen; Xiaoyan Jiang; Xiaowei Zhang; Xiaowei Ren; Wenchao Qu; Yang Yang; Hua Wan; Yi Chen; Jianping Zuo; Hualiang Jiang; Meiyu Geng; Jian Ding
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.